Regulation of pathological lymphangiogenesis requires factors distinct from those governing physiological lymphangiogenesis

Journal of Dermatological Science

Volumn 61, Issue 2, 2011, Pages 85-93

  Hirakawa, Satoshi ^a,b  

^a EHIME UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b EHIME UNIVERSITY   (Japan)

Author keywords

Angiogenesis; Metastasis; Tumor progression; Vascular development; Vascular endothelial growth factor

Indexed keywords

CHEMOKINE RECEPTOR CXCR4; DECTIN 2; HYALURONIC ACID; LYMPHATIC VESSEL ENDOTHELIAL HYALURONAN RECEPTOR 1; NEUROPILIN 2; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR PROX1; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG; VASCULOTROPIN C; VASCULOTROPIN RECEPTOR 3;

ANTIGEN PRESENTATION; CANCER INVASION; CELL TYPE; DOWN REGULATION; LIPID METABOLISM; LYMPH VESSEL; LYMPHANGIOGENESIS; MELANOMA; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVIEW; SKIN TUMOR; TRANSCRIPTION REGULATION; TUMOR GROWTH;

HUMANS; LYMPHANGIOGENESIS; LYMPHATIC METASTASIS; LYMPHATIC SYSTEM; SIGNAL TRANSDUCTION;

EID: 78951480367     PISSN: 09231811     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jdermsci.2010.11.020     Document Type: Review

References (92)

1. Alitalo K., Tammela T., Petrova T.V. Lymphangiogenesis in development and human disease. Nature 2005, 438(15):946-953.
2. Skobe M., Hawighorst T., Jackson D.G., Prevo R., Janes L., Velasco P., et al. Induction of tumor lymphangiogenesis by VEGF-C promotes breast cancer metastasis. Nature Medicine 2001, 7(2):192-198.
3. Stacker S.A., Caesar C., Baldwin M.E., Thornton G.E., Williams R.A., Prevo R., et al. VEGF-D promotes the metastatic spread of tumor cells via the lymphatics. Nature Medicine 2001, 7(2):186-191.
4. Mandriota S.J., Jussila L., Jeltsch M., Compagni A., Baetens D., Prevo R., et al. Vascular endothelial growth factor-C-mediated lymphangiogenesis promotes tumour metastasis. The EMBO Journal 2001, 20(4):672-682.
5. Karpanen T., Egeblad M., Karkkainen M.J., Kubo H., Yla-Herttuala S., Jaattela M., et al. Vascular endothelial growth factor C promotes tumor lymphangiogenesis and intralymphatic tumor growth. Cancer Research 2001, 61(5):1786-1790.
6. Oliver G., Detmar M. The rediscovery of the lymphatic system. Old and new insights into the development and biological function of lymphatic vascular system. Genes & Development 2002, 16(7):773-783.
7. Tammela T., Alitalo K. Lymphangiogenesis: molecular mechanisms and future promise. Cell 2010, 140(4):460-476.
8. Wang Y., Oliver G. Current views on the function of the lymphatic vasculature in health and disease. Genes & Development 2010, 24(19):2115-2126.
9. Wigle J.T., Oliver G. Prox1 function is required for the development of the murine lymphatic system. Cell 1999, 98(6):769-778.
10. Oliver G., Sosa-Pineda B., Geisendorf S., Spana E.P., Doe C.Q., Gruss P. Prox 1, a prospero-related homeobox gene expressed during mouse development. Mechanisms of Development 1993, 44:3-16.
11. Pajusola K., Aprelikova O., Korhonen J., Kaipainen A., Pertovaara L., Alitalo R., et al. FLT4 receptor tyrosine kinase contains seven immunoglobulin-like loops and is expressed in multiple human tissues and cell lines. Cancer Research 1992, 52(20):5738-5743.
12. Joukov V., Pajusola K., Kaipainen A., Chilov D., Lahtinen I., Kukk E., et al. A novel vascular endothelial growth factor, VEGF-C, is a ligand for the Flt4 (VEGFR-3) and KDR (VEGFR-2) receptor tyrosine kinases. The EMBO Journal 1996, 15(7):1751.
13. Karkkainen M.J., Haiko P., Sainio K., Partanen J., Taipale J., Petrova T.V., et al. Vascular endothelial growth factor C is required for sprouting of the first lymphatic vessels from embryonic veins. Nature Immunology 2004, 5(1):74-80.
14. Hirakawa S., Kodama S., Kunstfeld R., Kajiya K., Brown L.F., Detmar M. VEGF-A induces tumor and sentinel lymph node lymphangiogenesis and promotes lymphatic metastasis. The Journal of Experimental Medicine 2005, 201(7):1089-1099.
15. Hirakawa S., Brown L.F., Kodama S., Paavonen K., Alitalo K., Detmar M. VEGF-C-induced lymphangiogenesis in sentinel lymph nodes promotes tumor metastasis to distant sites. Blood 2007, 109(3):1010-1017.
16. Hirakawa S., Detmar M., Kerjaschki D., Nagamatsu S., Matsuo K., Tanemura A., et al. Nodal lymphangiogenesis and metastasis: Role of tumor-induced lymphatic vessel activation in extramammary Paget's disease. The American Journal of Pathology 2009, 175(5):2235-2248.
17. Hirakawa S, Tanemura A, Mori H, Katayama I, Hashimoto K. Multiple lymphadenopathy as an initial sign of extramammary Paget's disease. The British Journal of Dermatology; in press.
18. Baluk P., Fuxe J., Hashizume H., Romano T., Lashnits E., Butz S., et al. Functionally specialized junctions between endothelial cells of lymphatic vessels. The Journal of Experimental Medicine 2007, 204(10):2349-2362.
19. Harvey N.L., Srinivasan R.S., Dillard M.E., Johnson N.C., Witte M.H., Boyd K., et al. Lymphatic vascular defects promoted by Prox1 haploinsufficiency cause adult-onset obesity. Nature Genetics 2005, 37(10):1072-1081.
20. Machnik A., Neuhofer W., Jantsch J., Dahlmann A., Tammela T., Machura K., et al. Macrophages regulate salt-dependent volume and blood pressure by a vascular endothelial growth factor-C-dependent buffering mechanism. Nature Medicine 2009, 15(5):545-552.
21. Lim H.Y., Rutkowski J.M., Helft J., Reddy S.T., Swartz M.A., Randolph G.J., et al. Hypercholesterolemic mice exhibit lymphatic vessel dysfunction and degeneration. The American Journal of Pathology 2009, 175(3):1328-1337.
22. Banerji S., Ni J., Wang S.X., Clasper S., Su J., Tammi R., et al. LYVE-1, a new homologue of the CD44 glycoprotein, is a lymph-specific receptor for hyaluronan. The Journal of Cell Biology 1999, 144(4):789-801.
23. Gale N.W., Prevo R., Espinosa J., Ferguson D.J., Dominguez M.G., Yancopoulos G.D., et al. Normal lymphatic development and function in mice deficient for the lymphatic hyaluronan receptor LYVE-1. Molecular and Cellular Biology 2007, 27(2):595-604.
24. Luong M.X., Tam J., Lin Q., Hagendoorn J., Moore K.J., Padera T.P., et al. Lack of lymphatic vessel phenotype in LYVE-1/CD44 double knockout mice. Journal of Cellular Physiology 2009, 219(2):430-437.
25. Huang S.S., Liu I.H., Smith T., Shah M.R., Johnson F.E., Huang J.S. CRSBP-1/LYVE-l-null mice exhibit identifiable morphological and functional alterations of lymphatic capillary vessels. FEBS Letters 2006, 580(26):6259-6268.
26. Breiteneder-Geleff S., Matsui K., Soleiman A., Meraner P., Poczewski H., Kalt R., et al. Podoplanin, novel 43-kd membrane protein of glomerular epithelial cells, is down-regulated in puromycin nephrosis. The American Journal of Pathology 1997, 151(4):1141-1152.
27. Hirakawa S. From tumor lymphangiogenesis to lymphvascular niche. Cancer Science 2009, 100(6):983-989.
28. Uhrin P., Zaujec J., Breuss J.M., Olcaydu D., Chrenek P., Stockinger H., et al. Novel function for blood platelets and podoplanin in developmental separation of blood and lymphatic circulation. Blood 2010, 115(19):3997-4005.
29. Bertozzi C.C., Schmaier A.A., Mericko P., Hess 2F P.R., Zou Z., Chen M., et al. Platelets regulate lymphatic vascular development through CLEC-2-SLP-76 signaling. Blood 2010, 116(4):661-670.
30. Suzuki-Inoue K., Inoue O., Ding G., Nishimura S., Hokamura K., Eto K., et al. Essential in vivo roles of the C-type lectin receptor CLEC-2: embryonic/neonatal lethality of CLEC-2-deficient mice by blood/lymphatic misconnections and impaired thrombus formation of CLEC-2-deficient platelets. The Journal of Biological Chemistry 2010, 285(32):24494-24507.
31. Suzuki-Inoue K., Kato Y., Inoue O., Kaneko M.K., Mishima K., Yatomi Y., et al. Involvement of the snake toxin receptor CLEC-2, in podoplanin-mediated platelet activation, by cancer cells. The Journal of Biological Chemistry 2007, 282(36):25993-26001.
32. Abtahian F., Guerriero A., Sebzda E., Lu M.M., Zhou R., Mocsai A., et al. Regulation of blood and lymphatic vascular separation by signaling proteins SLP-76 and Syk. Science (New York, NY) 2003, 299(5604):247-251.
33. Pflicke H., Sixt M. Preformed portals facilitate dendritic cell entry into afferent lymphatic vessels. The Journal of Experimental Medicine 2009, 206(13):2925-2935.
34. Vondenhoff M.F., van de Pavert S.A., Dillard M.E., Greuter M., Goverse G., Oliver G., et al. Lymph sacs are not required for the initiation of lymph node formation. Development (Cambridge, England) 2009, 136(1):29-34.
35. Shields J.D., Kourtis I.C., Tomei A.A., Roberts J.M., Swartz M.A. Induction of lymphoidlike stroma and immune escape by tumors that express the chemokine CCL21. Science (New York, NY) 2010, 328(5979):749-752.
36. Eisenring M., vom Berg J., Kristiansen G., Saller E., Becher B. IL-12 initiates tumor rejection via lymphoid tissue-inducer cells bearing the natural cytotoxicity receptor NKp46. Nature Immunology 2010, 11(11):1030-1038.
37. Sabin F.R. On the origin of the lymphatic system from the veins and the development of the lymph hearts and thoracic duct in the pig. American Journal of Anatomy 1902, 1:367-391.
38. Srinivasan R.S., Dillard M.E., Lagutin O.V., Lin F.J., Tsai S., Tsai M.J., et al. Lineage tracing demonstrates the venous origin of the mammalian lymphatic vasculature. Genes & Development 2007, 21(19):2422-2432.
39. Lee S., Kang J., Yoo J., Ganesan S.K., Cook S.C., Aguilar B., et al. Prox1 physically and functionally interacts with COUP-TFII to specify lymphatic endothelial cell fate. Blood 2009, 113(8):1856-1859.
40. Yamazaki T., Yoshimatsu Y., Morishita Y., Miyazono K., Watabe T. COUP-TFII regulates the functions of Prox1 in lymphatic endothelial cells through direct interaction. Genes Cells 2009, 14(3):425-434.
41. Francois M., Caprini A., Hosking B., Orsenigo F., Wilhelm D., Browne C., et al. Sox18 induces development of the lymphatic vasculature in mice. Nature 2008, 456(7222):643-647.
42. Kerjaschki D., Huttary N., Raab I., Regele H., Bojarski-Nagy K., Bartel G., et al. Lymphatic endothelial progenitor cells contribute to de novo lymphangiogenesis in human renal transplants. Nature Medicine 2006, 12(2):230-234.
43. Maruyama K., Ii M., Cursiefen C., Jackson D.G., Keino H., Tomita M., et al. Inflammation-induced lymphangiogenesis in the cornea arises from CD11b-positive macrophages. The Journal of Clinical Investigation 2005, 115(9):2363-2372.
44. Maruyama K., Asai J., Ii M., Thorne T., Losordo D.W., D'Amore P.A. Decreased macrophage number and activation lead to reduced lymphatic vessel formation and contribute to impaired diabetic wound healing. The American Journal of Pathology 2007, 170(4):1178-1191.
45. He Y., Rajantie I., Ilmonen M., Makinen T., Karkkainen M.J., Haiko P., et al. Preexisting lymphatic endothelium but not endothelial progenitor cells are essential for tumor lymphangiogenesis and lymphatic metastasis. Cancer Research 2004 Jun 1, 64(11):3737-3740.
46. Schoppmann S.F., Birner P., Stockl J., Kalt R., Ullrich R., Caucig C., et al. Tumor-associated macrophages express lymphatic endothelial growth factors and are related to peritumoral lymphangiogenesis. The American Journal of Pathology 2002, 161(3):947-956.
47. Dadras S.S., Lange-Asschenfeldt B., Velasco P., Nguyen L., Vora A., Muzikansky A., et al. Tumor lymphangiogenesis predicts melanoma metastasis to sentinel lymph nodes. Modern Pathology 2005, 18(9):1232-1242.
48. Jeon B.H., Jang C., Han J., Kataru R.P., Piao L., Jung K., et al. Profound but dysfunctional lymphangiogenesis via vascular endothelial growth factor ligands from CD11b+ macrophages in advanced ovarian cancer. Cancer Research 2008, 68(4):1100-1109.
49. Iwata C., Kano M.R., Komuro A., Oka M., Kiyono K., Johansson E., et al. Inhibition of cyclooxygenase-2 suppresses lymph node metastasis via reduction of lymphangiogenesis. Cancer Research 2007, 67(21):10181-10189.
50. Kubota Y., Takubo K., Shimizu T., Ohno H., Kishi K., Shibuya M., et al. M-CSF inhibition selectively targets pathological angiogenesis and lymphangiogenesis. The Journal of Experimental Medicine 2009, 206(5):1089-1102.
51. Balch C.M., Gershenwald J.E., Soong S.J., Thompson J.F., Atkins M.B., Byrd D.R., et al. Final version of 2009 AJCC melanoma staging and classification. Journal of Clinical Oncology 2009, 27(36):6199-6206.
52. Dadras S.S., Paul T., Bertoncini J., Brown L.F., Muzikansky A., Jackson D.G., et al. Tumor lymphangiogenesis: a novel prognostic indicator for cutaneous melanoma metastasis and survival. The American Journal of Pathology 2003, 162(6):1951-1960.
53. Van der Auwera I., Cao Y., Tille J.C., Pepper M.S., Jackson D.G., Fox S.B., et al. First international consensus on the methodology of lymphangiogenesis quantification in solid human tumours. British Journal of Cancer 2006, 95(12):1611-1625.
54. Makinen T., Jussila L., Veikkola T., Karpanen T., Kettunen M.I., Pulkkanen K.J., et al. Inhibition of lymphangiogenesis with resulting lymphedema in transgenic mice expressing soluble VEGF receptor-3. Nature Medicine 2001, 7(2):199-205.
55. He Y., Kozaki K., Karpanen T., Koshikawa K., Yla-Herttuala S., Takahashi T., et al. Suppression of tumor lymphangiogenesis and lymph node metastasis by blocking vascular endothelial growth factor receptor 3 signaling. Journal of the National Cancer Institute 2002, 94(11):819-825.
56. Shimizu K., Kubo H., Yamaguchi K., Kawashima K., Ueda Y., Matsuo K., et al. Suppression of VEGFR-3 signaling inhibits lymph node metastasis in gastric cancer. Cancer Science 2004, 95(4):328-333.
57. Roberts N., Kloos B., Cassella M., Podgrabinska S., Persaud K., Wu Y., et al. Inhibition of VEGFR-3 activation with the antagonistic antibody more potently suppresses lymph node and distant metastases than inactivation of VEGFR-2. Cancer Research 2006, 66(5):2650-2657.
58. Rinderknecht M., Villa A., Ballmer-Hofer K., Neri D., Detmar M. Phage-derived fully human monoclonal antibody fragments to human vascular endothelial growth factor-C block its interaction with VEGF receptor-2 and 3. PloS one 2010, 5(8):e11941.
59. Albuquerque R.J., Hayashi T., Cho W.G., Kleinman M.E., Dridi S., Takeda A., et al. Alternatively spliced vascular endothelial growth factor receptor-2 is an essential endogenous inhibitor of lymphatic vessel growth. Nature Medicine 2009, 15(9):1023-1030.
60. Nakao S, Zandi S, Hata Y, Kawahara S, Arita R, Schering A, et al. Blood vessel endothelial VEGFR-2 delays lymphangiogenesis: an endogenous trapping mechanism links lymph- and angiogenesis. Blood; in press.
61. Hirakawa S., Hong Y.K., Harvey N., Schacht V., Matsuda K., Libermann T., et al. Identification of vascular lineage-specific genes by transcriptional profiling of isolated blood vascular and lymphatic endothelial cells. The American Journal of Pathology 2003, 162(2):575-586.
62. Nagy J.A., Vasile E., Feng D., Sundberg C., Brown L.F., Detmar M.J., et al. Vascular permeability factor/vascular endothelial growth factor induces lymphangiogenesis as well as angiogenesis. The Journal of Experimental Medicine 2002, 196(11):1497-1506.
63. Hong Y.K., Lange-Asschenfeldt B., Velasco P., Hirakawa S., Kunstfeld R., Brown L.F., et al. VEGF-A promotes tissue repair-associated lymphatic vessel formation via VEGFR-2 and the alpha1beta1 and alpha2beta1 integrins. FASEB Journal 2004, 18(10):1111-1113.
64. Baluk P., Yao L.C., Feng J., Romano T., Jung S.S., Schreiter J.L., et al. TNF-alpha drives remodeling of blood vessels and lymphatics in sustained airway inflammation in mice. The Journal of Clinical Investigation 2009, 119(10):2954-2964.
65. Yao L.C., Baluk P., Feng J., McDonald D.M. Steroid-resistant lymphatic remodeling in chronically inflamed mouse airways. The American Journal of Pathology 2010, 176(3):1525-1541.
66. Kajiya K., Hirakawa S., Ma B., Drinnenberg I., Detmar M. Hepatocyte growth factor promotes lymphatic vessel formation and function. The EMBO Journal 2005, 24(16):2885-2895.
67. Oka M., Iwata C., Suzuki H.I., Kiyono K., Morishita Y., Watabe T., et al. Inhibition of endogenous TGF-beta signaling enhances lymphangiogenesis. Blood 2008, 111(9):4571-4579.
68. Kunstfeld R., Hirakawa S., Hong Y.K., Schacht V., Lange-Asschenfeldt B., Velasco P., et al. VEGF-A plays a key role in the induction of chronic inflammation and the associated lymphangiogenic response. Blood 2004, 104(4):1048-1057.
69. Kajiya K., Hirakawa S., Detmar M. Vascular endothelial growth factor-A mediates ultraviolet B-induced impairment of lymphatic vessel function. The American Journal of Pathology 2006, 169(4):1496-1503.
70. Van den Eynden G.G., Vandenberghe M.K., van Dam P.J., Colpaert C.G., van Dam P., Dirix L.Y., et al. Increased sentinel lymph node lymphangiogenesis is associated with nonsentinel axillary lymph node involvement in breast cancer patients with a positive sentinel node. Clinical Cancer Research 2007, 13(18 Pt 1):5391-5397.
71. Clasper S., Royston D., Baban D., Cao Y., Ewers S., Butz S., et al. A novel gene expression profile in lymphatics associated with tumor growth and nodal metastasis. Cancer Research 2008, 68(18):7293-7303.
72. Yuan L., Moyon D., Pardanaud L., Breant C., Karkkainen M.J., Alitalo K., et al. Abnormal lymphatic vessel development in neuropilin 2 mutant mice. Development (Cambridge, England) 2002, 129(20):4797-4806.
73. Caunt M., Mak J., Liang W.C., Stawicki S., Pan Q., Tong R.K., et al. Blocking neuropilin-2 function inhibits tumor cell metastasis. Cancer Cell 2008, 13(4):331-342.
74. Alvarez D., Vollmann E.H., von Andrian U.H. Mechanisms and consequences of dendritic cell migration. Immunity 2008, 29(3):325-342.
75. Debes G.F., Arnold C.N., Young A.J., Krautwald S., Lipp M., Hay J.B., et al. Chemokine receptor CCR7 required for T lymphocyte exit from peripheral tissues. Nature Immunology 2005, 6(9):889-894.
76. Johnson L.A., Jackson D.G. Inflammation-induced secretion of CCL21 in lymphatic endothelium is a key regulator of integrin-mediated dendritic cell transmigration. International Immunology 2010, 22(10):839-849.
77. Issa A., Le T.X., Shoushtari A.N., Shields J.D., Swartz M.A. Vascular endothelial growth factor-C and C-C chemokine receptor 7 in tumor cell-lymphatic cross-talk promote invasive phenotype. Cancer Research 2009, 69(1):349-357.
78. Muller A., Homey B., Soto H., Ge N., Catron D., Buchanan M.E., et al. Involvement of chemokine receptors in breast cancer metastasis. Nature 2001, 410(6824):50-56.
79. Takeuchi H., Fujimoto A., Tanaka M., Yamano T., Hsueh E., Hoon D.S. CCL21 chemokine regulates chemokine receptor CCR7 bearing malignant melanoma cells. Clinical Cancer Research 2004, 10(7):2351-2358.
80. Wiley H.E., Gonzalez E.B., Maki W., Wu M.M., Hwang S.T. Expression of CC chemokine receptor-7 and regional lymph node metastasis of B16 murine melanoma. Journal of the National Cancer Institute 2001, 93(21):1638-1643.
81. Kabashima K., Shiraishi N., Sugita K., Mori T., Onoue A., Kobayashi M., et al. CXCL12-CXCR4 engagement is required for migration of cutaneous dendritic cells. The American Journal of Pathology 2007, 171(4):1249-1257.
82. Kucia M., Reca R., Miekus K., Wanzeck J., Wojakowski W., Janowska-Wieczorek A., et al. Trafficking of normal stem cells and metastasis of cancer stem cells involve similar mechanisms: pivotal role of the SDF-1-CXCR4 axis. Stem cells (Dayton, Ohio) 2005, 23(7):879-894.
83. Harrell M.I., Iritani B.M., Ruddell A. Tumor-induced sentinel lymph node lymphangiogenesis and increased lymph flow precede melanoma metastasis. The American Journal of Pathology 2007, 170(2):774-786.
84. Qian C.N., Berghuis B., Tsarfaty G., Bruch M., Kort E.J., Ditlev J., et al. Preparing the " soil": the primary tumor induces vasculature reorganization in the sentinel lymph node before the arrival of metastatic cancer cells. Cancer Research 2006, 66(21):10365-10376.
85. Angeli V., Ginhoux F., Llodra J., Quemeneur L., Frenette P.S., Skobe M., et al. B cell-driven lymphangiogenesis in inflamed lymph nodes enhances dendritic cell mobilization. Immunity 2006, (February):203-215.
86. Halin C., Tobler N.E., Vigl B., Brown L.F., Detmar M. VEGF-A produced by chronically inflamed tissue induces lymphangiogenesis in draining lymph nodes. Blood 2007, 110(9):3158-3167.
87. Kataru R.P., Jung K., Jang C., Yang H., Schwendener R.A., Baik J.E., et al. Critical role of CD11b+ macrophages and VEGF in inflammatory lymphangiogenesis, antigen clearance, and inflammation resolution. Blood 2009, 113(22):5650-5659.
88. Asellius G. De lactibus sive lacteis venis, quarto vasorum mesarai corum genere nova invento 1627, Mediolani, Milan.
89. Reddy S.T., van der Vlies A.J., Simeoni E., Angeli V., Randolph G.J., O'Neil C.P., et al. Exploiting lymphatic transport and complement activation in nanoparticle vaccines. Nature Biotechnology 2007, 25(10):1159-1164.
90. Proulx S.T., Luciani P., Derzsi S., Rinderknecht M., Mumprecht V., Leroux J.C., et al. Quantitative imaging of lymphatic function with liposomal indocyanine green. Cancer Research 2010, 70(18):7053-7062.
91. Kajiya K., Sawane M., Huggenberger R., Detmar M. Activation of the VEGFR-3 pathway by VEGF-C attenuates UVB-induced edema formation and skin inflammation by promoting lymphangiogenesis. Journal of Investigative Dermatology 2009, 129(5):1292-1298.
92. Huggenberger R., Ullmann S., Proulx S.T., Pytowski B., Alitalo K., Detmar M. Stimulation of lymphangiogenesis via VEGFR-3 inhibits chronic skin inflammation. The Journal of Experimental Medicine 2010, 207(10):2255-2269.